If you have been reading about Thymalfasin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
It was during this early period when Jung was an assistant at the Anatomical Institute at Basel University, that he took an interest in paleoanthropology and the revolutionary discoveries of Homo erectus and Neanderthal fossils. These formative experiences contributed to his fascination with the evolutionary past of humanity and his belief that an ancient evolutionary layer in the psyche, represented by early fossil hominins, is still evident in the psychology of modern humans. Despite showing promise in medicine and almost choosing to specialise in surgery, Jung, to the dismay of his family and professors, decided to become a psychiatrist after reading a Richard von Krafft-Ebing's Textbook of Psychiatry. In December 1900, he moved to Zürich and began as an intern (voluntary doctor) at the Burghölzli psychiatric hospital under the psychiatrist Eugen Bleuler. Bleuler was already in communication with Sigmund Freud and introduced Jung to his work. At Burghölzli, Jung became interested in 'dementia praecox' (former name for schizophrenia, a term that Bleuler came up with). Before this he had mainly been interested in neurosis, but psychotic patients would become his primary concern for the rest of his career. In 1902, on leave from Burghölzli, Jung studied with Pierre Janet in Paris, and later equated his view of the complex with Janet's idée fixe subconsciente. In 1905, Jung was appointed as a permanent 'senior' doctor at Burghölzli and became a lecturer Privatdozent in the medical faculty of Zurich University.
Glyceraldehyde-3-phosphate can double up to form larger sugar molecules like glucose and fructose. These molecules are processed, and from them, the still larger sucrose, a disaccharide commonly known as table sugar, is made, though this process takes place outside of the chloroplast, in the cytoplasm. Alternatively, glucose monomers in the chloroplast can be linked together to make starch, which accumulates into the starch grains found in the chloroplast. Under conditions such as high atmospheric CO2 concentrations, these starch grains may grow very large, distorting the grana and thylakoids. The starch granules displace the thylakoids, but leave them intact. Waterlogged roots can also cause starch buildup in the chloroplasts, possibly due to less sucrose being exported out of the chloroplast (or more accurately, the plant cell). This depletes a plant's free phosphate supply, which indirectly stimulates chloroplast starch synthesis. While linked to low photosynthesis rates, the starch grains themselves may not necessarily interfere significantly with the efficiency of photosynthesis, and might simply be a side effect of another photosynthesis-depressing factor.
Another disadvantage is that the input cell volume must be free of large cell clumps, which requires a pre-processing step (typically, by sonication). If cell clumps are not removed prior to processing, clogging of the valve occurs, and the unit must be cleaned thoroughly before the processing can continue. As a result, many protein purification labs find that the use of lysozyme and sonication is sufficient for routine bacterial protein expression. Other technologies, such as sonication and ball mills, are available for many of the same purposes, and have their own advantages and disadvantages. For example, sonication can generate high shear forces that break cellular DNA into small fragments. With a French press, the shear force can be carefully modulated by adjusting the piston pressure. The Press provides a single pass through the point of maximum shear force, limiting damage to delicate biological structures due to repeated shear, as occurs in other disruption methods.
=== A balanced nervous system === In the balanced nervous system with required cognitive functions, the sympathetic (SNS) and parasympathetic nervous systems (PNS) operate in synergy while opposing each other. Stimulation of the SNS boosts body activity and attention: it raises heart rate and blood pressure. In contrast, stimulation of the PNS is the rest-and-digest state: it reduces blood pressure and heart rate. The nervous system interplays with the immune system. Through these interactions, the nervous and immune systems ensure the nervous system maintains immune homeostasis.
== Criticism == In a 2002 lawsuit against McDonald's, a judge commented that Chicken McNuggets are a "McFrankenstein" creation. The judge identified that rather than being merely chicken fried in a pan, McNuggets included elements not utilized by the home cook, including unusual sounding ingredients such as extracts of rosemary, vitamins (niacin, thiamine mononitrate, riboflavin, and folic acid) all of which are common in enriched flour, and leavening (baking soda, calcium lactate, etc.). The 2004 documentary Super Size Me states that "[o]riginally created from old chickens that can no longer lay eggs, McNuggets are now made from chickens with unusually large breasts. They're stripped from the bone, and ground-up into a sort of 'chicken mash', which is then combined with all sorts of stabilizers and preservatives, pressed into familiar shapes, breaded, deep-fried, freeze-dried, and then shipped to a McDonald's near you." Super Size Me also alleged inclusion of ingredients such as TBHQ, polydimethylsiloxane, and others not used by a typical home cook. This was subsequently restated by CNN. Marion Nestle, a New York University professor and author of What to Eat, says that the ingredients in McNuggets probably pose no health risks. Before August 2016, dimethylpolysiloxane and TBHQ were listed as ingredients in the McNuggets cooking process. According to Lisa McComb, a media relations representative for McDonald's, dimethylpolysiloxane is used as a matter of safety to keep the frying oil from foaming.
Sources: en.wikipedia.org
===== Strontium/calcium ratio anomaly ===== Time can be attributed to coral geochemistry anomalies by correlating strontium/calcium minimums with sea surface temperature (SST) maximums to data collected from NINO 3.4 SSTA.
According to these principles, there must exist in space megastructures of great size, emitting a lot of energy and information, and existing for billions of years, while being compact enough to rapidly exchange large amounts of data between them. A supercivilization would thus create a technological structure of cosmic dimensions. As an example, Kardashev cites Freeman Dyson's megastructure, in the form of a sphere of several astronomical units in diameter. Other phenomena may indicate highly technological activities, such as artificially exploding stars or the changing of stellar orbits to store mass and energy. Giant molecular clouds also hold great potential for astroengineering. Kardashev even raises the possibility of a supercivilization reshaping the entire galaxy. Then he evokes the theoretical and mathematical possibility of the existence of a megastructure in the form of a disk rotating on itself at a constant angular velocity. According to him, the search for intelligent signals should be directed to the detection of such megastructures at the characteristic radiation (20 μm). Quasars or galactic centers can be excellent candidates to testify to the existence of a supercivilization since they emit strong infrared radiation, which indicates a solid structure. The astronomer advises to look for these objects in a wavelength range from a few microns to a few millimeters. Large intelligent structures can also be detected by the fact that they screen or reflect the surrounding radiation.
Portugal's manufacturing industry accounted for 21.2% of the country's total GDP as of 2024, down from an annual average of 26% over the period between 1953 and 1973. The lower contribution of manufacturing to Portugal's economy has led to lower real GDP growth rates between 1974 and 2019 than during the period between 1950 and 1973. As of 2025, Portugal's automobile industry produced the biggest share of the country's exports. The automobile industry accounts for 20.2% of the country manufacturing exports and 82.8% of the total value of its exports employing 43.247 workers in 2020. Portugal's service sector accounted for 76.5% of the country's total economic output as of 2024. Tourism, retail, and telecommunication are all major industries. Tourism represented 11.8% of the Portugal's total GDP as of 2025. Portugal attracted nearly 30 million international tourists in 2025, ranking 15th in the world in that year for inbound tourism.
=== Presumptive substance testing === Presumptive substance tests attempt to identify a suspicious substance, material or surface where traces of drugs are thought to be, instead of testing individuals through biological methods such as urine or hair testing. The test involves mixing the suspicious material with a chemical in order to trigger a color change to indicate if a drug is present. Most are now available over-the-counter for consumer use, and do not require a lab to read results.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.